Business ❯ Pharmaceuticals

Research and Development

Clinical Trials Investment Innovation Cell Therapy Investment Decisions Natural Products Specialty Medicines Global Operations KarXT Biologics Partnerships Drug Development Manufacturing Specialty Chemicals Life Sciences Industry Trends Investment Trends Drug Trials Drug Formulations Market Strategy Product Development Tax Incentives Collaboration Intellectual Property Innovative Therapies Artificial Intelligence Clinical Research Collaborations Drug Discovery Corporate Strategy Radioisotope Production

Telix to Acquire German Isotope Maker ITM in Up to $2.35 Billion Deal

The transaction is intended to lock in supplies of lutetium-177, actinium-225 and terbium-161, speed commercial rollout, with up to $700 million in payments tied to regulatory approvals and sales milestones.

Bristol Myers Squibb Buys Second NVIDIA DGX SuperPOD Built on Vera Rubin

NVIDIA Launches BioNeMo Agent Toolkit for Agentic Life‑Sciences Workflows

XtalPi Wins Funded Partnership to Discover Oral Small‑Molecule for Challenging GPCR

Pfizer Moves 25-Valent Infant Pneumococcal Shot Into Late-Stage Trial After Mid-Stage Gains

Eton Pharma Launches FDA-Approved Desmota as Revenue and Margins Jump

Merck and Mayo Clinic Launch AI Drug Discovery Collaboration Using Platform_Orchestrate

AstraZeneca Pauses £200m Cambridge Plan as Merck Axes £1bn London Hub

Amgen Commits Over $600 Million to New R&D Center at Thousand Oaks Headquarters